糖皮质激素治疗非动脉炎性前部缺血性视神经病变的研究进展  

Advances in glucocorticoid therapy for nonarteritic anterior ischemic optic neuropathy

作　　者：陈文瑜 艾明[1] 陈婷 Chen Wenyu;Ai Ming;Chen Ting(Eye Center,Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院眼科中心,武汉430060

出　　处：《中国医药》2022年第3期477-480,共4页China Medicine

摘　　要：非动脉炎性前部缺血性视神经病变(NAION)是一种常见的急性视神经病变,表现为无痛性突发单眼或双眼视力下降及特征性视野缺损,伴有视盘水肿。糖皮质激素具有促进视盘水肿消退和减轻非特异性细胞炎症等作用,可应用于NAION急性期治疗。但随着检测技术的提升与高级别临床试验证据的报道,有学者对糖皮质激素治疗NAION的有效性及安全性提出了质疑。本文对近年来糖皮质激素治疗NAION的研究进展进行综述。Nonarteritic anterior ischemic optic neuropathy(NAION)is a common acute optic neuropathy,which is characterized by painless sudden monocular or binocular visual loss,characteristic visual field defect and accompanied by optic disc edema and so on.Glucocorticoid can promote the regression of optic disc edema and reduce nonspecific cell inflammation.It is used to treat the acute NAION.However,with the improvement of detection technology and the report of high-level clinical trial evidence,scholars questioned the effectiveness and safety of glucocorticoid in the treatment of NAION.This paper reviews the theoretical basis and clinical research progress of glucocorticoid in the treatment of NAION in recent years.

关 键 词：非动脉炎性前部缺血性视神经病变 糖皮质激素 视神经病变 视力下降 视野缺损 

分 类 号：R774.6[医药卫生—眼科]